Dr. Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Limited sponsored Phase I Clinical Trial that is being conducted at the Medical College of Wisconsin, joins Natalie Stoberman from the Proactive studios to discuss the latest updates from its treatment for recurring glioblastoma patients.
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively.